(Q35921638)

11 August 2017

1 reference

title

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer (English)

1 reference

11 August 2017

1 reference

Munkarah AR

1

1 reference

11 August 2017

Coleman RL

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

95

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

273-280

1 reference

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Hepatic resection for metachronous metastases from ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Resection of recurrent ovarian or fallopian tube carcinoma involving the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Cisplatin/carboplatin cross-resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.018

10.1016/J.YGYNO.2004.09.018

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference